Business
PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the Midwest Surgical Association 2022 Annual Meeting
Efficacy Data of D-PLEX100 in the Prevention of Post-Abdominal Surgery Incisional Infection in High-Risk Patients will be Presented During a Podium
About this update from Polypid Ltd.
[{"type":"text","content":"Efficacy Data of D-PLEX100 in the Prevention of Post-Abdominal Surgery Incisional Infection in High-Risk Patients will be Presented During a Podium Presentation PETACH TIKVA, Israel, July 25, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Phase 2 clinical data for D-PLEX100 will be highlighted in a podium presentation at the Midwest Surgical Association 2022 Annual Meeting being held on August 7-9, 2022, at the Grand Hotel in Mackinac Island, Michigan. Midwest Surgical Association 2022 Annual Meeting: Presentation Title:Reduction in Surgical Site Infections by Localized Administration with D-PLEX100 in Patients with Multiple Risk Factors Undergoing Colorectal SurgeryPresenter:Anthony J. Senagore, M.D., Senior Medical Director of PolyPidDate/Time:Monday, August 8, 2022, Scientific Session I, 8:15 a.m. – 8:30 a.m. The presentation will be available on http://www.polypid.com/ following its conclusion. About PolyPidPolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients, enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trials for the prevention of soft tissue abdominal and sternal bone surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for treatment of solid tumors, beginning with glioblastoma. For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn. Contacts: PolyPid Ltd. Ori WarshavskyCOO – US908-858-5995 Investors:Bob YedidLifeSci [email protected] Media Contact:Nechama [email protected] \nSource: PolyPid Ltd.","length":5737,"tagName":"div"}]